The Psoriasis Therapeutic Clinical Intelligence report provides an in-depth assessment of the R&D competitive landscape for psoriasis (PsO)—from a clinical perspective. Additionally, the analysis highlights select compounds in the pipeline for Psoriatic Arthritis (PsA). The scope of the report focuses on competitive biologic and novel small molecule products in development and specifically captures key data on clinical trial design and data results for the products that have the potential to alter the market dynamics in psoriasis over the next 3-7 years.
This methodological approach is intended to provide insight into the strategic opportunities and challenges, as well as the clinical hurdles facing PsO/PsA drug developers.
Clients utilize the report as a resource to support key decisions including:
- Analyzing the overall depth and breadth of the competitive landscape within a therapeutic area - Assessing target product profiles of key current and future competitors - Benchmarking competitor clinical trial designs and results - Developing clinical analogues to support go-no-go decisions - Identifying clinical hurdles posed by competitors - Designing clinical trials more effectively to maximize a product’s penetration
Reports contain synthesized information and analysis of clinical development activities for key marketed and pipeline products within multiple therapeutic categories and generally include the following data points:
Product Overview: Mechanism of Action, Developing Companies, Indications and Phase of Development.
Clinical Trial Assessments: Detailed evaluations of completed and ongoing competitor studies that capture key elements of the study protocol including:
- Trial design - Start and end dates - Study size and patient type - Number of participating sites - Dosing regimen - Endpoints - Safety and efficacy results
Product samples
A sample for this product is available. Please Login/Register to download this sample.
